Correction: Alz Res Therapy 16, 228 (2024)
10.1186/s13195-024-01594-6
Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section.
The current wording erroneously states that CETP inhibitors decreases Apo-E concentration:
However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer’s disease (AD).
Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read:
However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer’s disease (AD).
The original article [1] has been updated.
Footnotes
The online version of the original article can be found at 10.1186/s13195-024-01594-6.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Schmidt AF, Davidson MH, Ditmarsch M, et al. Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysis. Alz Res Therapy. 2024;16:228. 10.1186/s13195-024-01594-6. [DOI] [PMC free article] [PubMed] [Google Scholar]